HIV Characteristics and Life Cycle
The human immunodeficiency virus is an RNA-containing retrovirus. Successful pharmacotherapy requires targeting all eight stages of its reproduction. The viral life cycle begins with adsorption, where the gp120 glycoprotein and CD4 receptors with the CCR5 coreceptor mediate attachment to the target cell surface. This is followed by penetration—the fusion of the virion envelope with the cell membrane.
Inside the cell, reverse transcription takes place, during which double-stranded DNA (the provirus) is synthesized using viral RNA as a template. This process is catalyzed by the enzyme reverse transcriptase. The synthesized DNA enters the host cell nucleus, where integrase facilitates its insertion into the human genome. The integrated provirus can remain inactive for years, creating a risk of recurrence.
Protein Synthesis and Viral Maturation
Following integration, viral genetic information is expressed via transcription of the proviral DNA into mRNA and the synthesis of new viral RNAs. Ribosomes translate the mRNA into precursor viral proteins. The provirus encodes three critically important groups of proteins:
- Enzymes: Reverse transcriptase, integrase, and protease.
- Polypeptide precursors: Long polypeptide chains.
- Transmembrane protein (gp160): Spans the lipid envelope and mediates cell entry.
During the final stages of assembly and budding, the viral particle is formed. In the maturation process, the viral protease cleaves long polypeptide chains into individual functional proteins, rendering the new virion infectious.
Targets of Antiretroviral Therapy
Pharmacological intervention aims to block key steps in viral reproduction. Primary targets include viral enzymes and the cell entry process:
- Early stages: Blockade of the CCR5 coreceptor (Maraviroc) and inhibition of fusion (Enfuvirtide).
- Genetic material synthesis: Inhibition of reverse transcriptase (Zidovudine) and integrase (Raltegravir).
- Late stages and maturation: Inhibition of HIV protease (Indinavir, Ritonavir).
Widely used drug classes include structural analogues of nucleosides and nucleotides, as well as non-nucleoside reverse transcriptase inhibitors.